Trial Profile
Lenalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2015
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms QoL-ESC RevMDS
- 27 Jul 2011 New trial record